Can MiR-503 be used as a marker in diabetic patients with ischemic stroke?
Authors:
- Saba SheikhbahaeiSSSaba Sheikhbahaei
- Danesh ManizhehDMDanesh Manizheh
- Saadatnia MohammadSMSaadatnia Mohammad
- Tajaddini Mohamad HasanTHTajaddini Mohamad Hasan
- Nazemian SamanNSNazemian Saman
- Rafiee LalehRLRafiee Laleh
- Motieian MahsaMMMotieian Mahsa
- Amoushahi Khouzani SanazASAmoushahi Khouzani Sanaz
- Haghjooy Javanmard ShaghayeghHSHaghjooy Javanmard Shaghayegh
Open Access
- 29 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 19 (1) , 1-7
Abstract
Some microRNAs are involved in diabetes pathology and some are known to have role in stroke. MiR-503 causes endothelial dysfunction in diabetic patients, predisposing to ischemia. There has been no study evaluating Mir-503 level in diabetic patients with or without ischemic stroke. We designed a cross-sectional study to assess and compare serum level of MiR-503 in 4 groups of diabetic patients with ischemic stroke (I), non-diabetic patients with stroke (II), diabetic patients (III), and healthy controls (IV) in acute phase and 3 months later. Our data analysis showed that mean relative expression of MiR-503 in group (I) was significantly higher than 3 other groups (p < 0.05). The level of miR-503 was related to the patients’ fasting blood glucose, Cholesterol level, NIHSS score and acute–phase modified Rankin Scale (mRS) (r = 0.49, p = 0.001, r = 0.5, p = 0.009, r = 0.45, p = 0.009, r = 0.48, p = 0.003, CI = 95%). Relative expression of miR in patients with mRS ≤ 2 (good outcome) was lower than in patients with mRS > 2 (poor outcome) (p = 0.008). After 3 months, level of miR decreased significantly only in group (I) (p = 0.002). Mean relative expression of miR-503 in chronic phase was not significantly different among groups (p-value> 0.05). There was no relation between miRNA level and mRS in chronic phase. Hyperglycemia and ischemia together raise the level of MiR-503 acutely but it does not remain at high level after 3 months. Although higher miR was related to more disability in acute phase, it does not affect long-term outcome in ischemic patients. As MiR-503 is stable enough in blood it can be used as a potential diagnostic marker of an ischemic stroke in diabetic patient. Its level also is an indicator of stroke severity and patients’ short-term outcome. It is recommended to study whether antagomiR-503 is a new therapeutic agent reducing the severity of and disability due to stroke.Keywords
This publication has 41 references indexed in Scilit:
- Overview of MicroRNA Biogenesis, Mechanisms of Actions, and CirculationFrontiers in Endocrinology, 2018
- Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and OutcomesThe American Journal of the Medical Sciences, 2016
- Diabetes is an Independent Risk Factor for Stroke Recurrence in Stroke Patients: A Meta-analysisJournal of Stroke and Cerebrovascular Diseases, 2015
- miR-375, a microRNA related to diabetesGene, 2014
- Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010The Lancet Global Health, 2013
- Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1Journal of Molecular and Cellular Cardiology, 2012
- Review article: Platelet abnormalities in diabetes mellitusDiabetes & Vascular Disease Research, 2010
- Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic reviewThe Lancet Neurology, 2009
- The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target geneProceedings of the National Academy of Sciences, 2008
- Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic PatientsStroke, 2001